A new trading day began on Friday, with Prime Medicine Inc (NASDAQ: PRME) stock price up 26.19% from the previous day of trading, before settling in for the closing price of $1.26. PRME’s price has ranged from $1.12 to $8.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. Meanwhile, its annual earnings per share averaged 19.67%. With a float of $51.97 million, this company’s outstanding shares have now reached $131.16 million.
Considering the fact that the conglomerate employs 214 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 28.62%.
Prime Medicine Inc (PRME) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 19.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.97% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Here are Prime Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 54.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Compared to the last year’s volume of 1.33 million, its volume of 1.67 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.64%. Additionally, its Average True Range was 0.19.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 19.19%, which indicates a significant decrease from 63.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.25% in the past 14 days, which was higher than the 108.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6285, while its 200-day Moving Average is $3.0203. Nevertheless, the first resistance level for the watch stands at $1.7157 in the near term. At $1.8414, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0828. If the price goes on to break the first support level at $1.3486, it is likely to go to the next support level at $1.1072. Should the price break the second support level, the third support level stands at $0.9815.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
With a market capitalization of 208.76 million, the company has a total of 131,294K Shares Outstanding. Currently, annual sales are 2,980 K while annual income is -195,880 K. The company’s previous quarter sales were 1,450 K while its latest quarter income was -51,890 K.
